Search results for "treatment."

showing 10 items of 17500 documents

What can evolutionary rescue tell us about the emergence of new resistant bacteria?

2017

0301 basic medicineMicrobiology (medical)GeneticsBacteriaGene Transfer HorizontalPhage therapymedicine.medical_treatment030106 microbiologyBacterial InfectionsBiologyMicrobiologyAnti-Bacterial AgentsMicrobiologyEvolution Molecular03 medical and health sciencesResistant bacteriaAntibiotic resistanceDrug Resistance BacterialMutationHorizontal gene transfermedicineHumansSelection GeneticEvolutionary rescueFuture Microbiology
researchProduct

No effect of vancomycin MIC ≥ 1.5 mg/L on treatment outcome in methicillin-susceptible Staphylococcus aureus bacteraemia

2018

International audience; The vancomycin minimum inhibitory concentration (MIC) has been shown to affect the outcome of methicillin-susceptible Staphylococcus aureus (MSSA) bacteraemia. In this study, the outcomes of patients with MSSA bacteraemia with a vancomycin MIC ≥ 1.5 mg/L were assessed. A prospective cohort of patients with MSSA bacteraemia in two tertiary-care hospitals was collected. The vancomycin MIC was determined by Etest. Staphylococcus aureus strains were categorised as low (<1.5 mg/L) or high (≥1.5 mg/L) vancomycin MIC. First- and second-line treatments were recorded and classified as optimal, appropriate and inappropriate. The primary endpoint was 30-day mortality. A total o…

0301 basic medicineMicrobiology (medical)MaleMethicillin-Resistant Staphylococcus aureusmedicine.medical_specialtyStaphylococcus aureusmedicine.drug_classmedicine.medical_treatment030106 microbiologyAntibioticsBacteremiaMicrobial Sensitivity Testsmedicine.disease_cause03 medical and health sciencesMinimum inhibitory concentrationVancomycin[ SDV.MP ] Life Sciences [q-bio]/Microbiology and ParasitologyInternal medicine[ SDV.MHEP ] Life Sciences [q-bio]/Human health and pathologymedicineHumansPharmacology (medical)Prospective StudiesMortalityProspective cohort studyEtestDialysisAgedAged 80 and overMinimum inhibitory concentrationbusiness.industryGeneral MedicineMiddle AgedStaphylococcal Infectionsbiochemical phenomena metabolism and nutritionbacterial infections and mycoses3. Good healthAnti-Bacterial Agents[SDV.MP]Life Sciences [q-bio]/Microbiology and ParasitologyInfectious DiseasesStaphylococcus aureusCatheter-Related InfectionsVancomycinBacteraemiaFemaleMethicillin Susceptible Staphylococcus Aureusbusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologymedicine.drug
researchProduct

The clinical impact of PCR‐based point‐of‐care diagnostic in respiratory tract infections in children

2020

Abstract Background Children are commonly affected by respiratory tract infections. Based on clinical symptoms, laboratory evaluation, and imaging, the causative pathogen often cannot be delineated. Point‐of‐care‐testing systems that provide an opportunity for fast detection of common viruses and some bacteria can therefore influence treatment's options. We aimed to examine whether the Biofire® FilmArray® has an effect on antibiotic treatment, duration of antibiotic therapy, and length of hospital stay within a pediatric cohort. Methods We included children who were admitted to inpatient treatment with an acute respiratory tract infection from 02/2017 to 04/2018 using the FA respiratory pan…

0301 basic medicineMicrobiology (medical)Malemedicine.medical_specialtyPathogen detectionAdolescentmedicine.drug_classPoint-of-care testingPoint-of-Care SystemsAntibioticsClinical BiochemistryAdenovirus Infections Human03 medical and health sciences0302 clinical medicineInternal medicinepoint‐of‐care‐testingMedicineImmunology and AllergyHumansChildAcute respiratory tract infectionRespiratory Tract InfectionsResearch ArticlesPoint of careBiochemistry medicalPast medical historyRespiratory tract infectionsbusiness.industryBiofire® FilmArray®acute respiratory tract infectionsBiochemistry (medical)Public Health Environmental and Occupational HealthInfantHematologyLength of StayAnti-Bacterial AgentsMedical Laboratory Technology030104 developmental biology030220 oncology & carcinogenesisCase-Control StudiesChild PreschoolCohortantibiotic treatmentmultiplex RT‐PCRFemalebusinessMultiplex Polymerase Chain ReactionResearch ArticleJournal of Clinical Laboratory Analysis
researchProduct

Long‐term treatment with the oncolytic ECHO‐7 virus Rigvir of a melanoma stage IV M1c patient, a small cell lung cancer stage IIIA patient, and a his…

2016

Oncolytic virotherapy is a recent addition to cancer treatment. Here, we describe positive treatment outcomes in three patients using Rigvir virotherapy. One of the patients is diagnosed with melanoma stage IV M1c, one with small cell lung cancer stage IIIA, and one with histiocytic sarcoma stage IV. The diagnoses of all patients are verified by histology or cytology. All patients started Rigvir treatment within a few months after being diagnosed and are currently continuing Rigvir treatment. The degree of regression of the disease has been determined by computed tomography. Safety assessment of adverse events graded according to NCI CTCAE did not show any value above grade 1 during Rigvir(…

0301 basic medicineMicrobiology (medical)Oncologymedicine.medical_specialtyPathologymedicine.medical_treatmentHistiocytic sarcomaPathology and Forensic Medicine03 medical and health sciences0302 clinical medicineInternal medicineImmunology and AllergyMedicineVirotherapyAdverse effectProspective cohort studybusiness.industryMelanomaGeneral MedicineImmunotherapymedicine.diseaseOncolytic virus030104 developmental biology030220 oncology & carcinogenesisSmall Cell Lung CarcinomabusinessAPMIS
researchProduct

Bacteriophages: Protagonists of a Post-Antibiotic Era

2018

This article belongs to the Special Issue Bacteriophages: Alternatives to Antibiotics and Beyond.

0301 basic medicineMicrobiology (medical)Phage therapyPhage therapyAntibiotic resistancemedicine.drug_classmedicine.medical_treatmentAntibioticsReviewBiologyBiochemistryMicrobiologyEnzybiotics03 medical and health sciencesAntibiotic resistancemedicineBacteriophagesPharmacology (medical)General Pharmacology Toxicology and Pharmaceuticsbusiness.industrylcsh:RM1-950Ecological safetyEnzybioticsBiotechnologylcsh:Therapeutics. Pharmacology030104 developmental biologyInfectious DiseasesPhage displaybusinessAntibiotics
researchProduct

Phages for biofilm removal

2020

This article belongs to the Special Issue Phage Therapy, Lysin Therapy, and Antibiotics, a Trio Due to Come.

0301 basic medicineMicrobiology (medical)Phage therapyPhage therapyAntibiotic resistancemedicine.medical_treatmentviruses030106 microbiologyReviewBiochemistryMicrobiologycomplex mixturesbiofilmMicrobiologyBacteriophage03 medical and health sciencesAntibiotic resistancemedicinePharmacology (medical)General Pharmacology Toxicology and PharmaceuticsBacteriophagebiologyChemistrylcsh:RM1-950Polymeric matrixBiofilmbiochemical phenomena metabolism and nutritionbiology.organism_classificationlcsh:Therapeutics. Pharmacology030104 developmental biologyInfectious DiseasesBiofilmsbacteriaBacteria
researchProduct

Scoping the effectiveness and evolutionary obstacles in using plasmid-dependent phages to fight antibiotic resistance

2016

Aim: To investigate the potential evolutionary obstacles in the sustainable therapeutic use of plasmid-dependent phages to control the clinically important conjugative plasmid-mediated dissemination of antibiotic resistance genes to pathogenic bacteria. Materials &amp; methods: The lytic plasmid-dependent phage PRD1 and the multiresistance conferring plasmid RP4 in an Escherichia coli host were utilized to assess the genetic and phenotypic changes induced by combined phage and antibiotic selection. Results &amp; conclusions: Resistance to PRD1 was always coupled with either completely lost or greatly reduced conjugation ability. Reversion to full conjugation efficiency was found to be rare…

0301 basic medicineMicrobiology (medical)Phage therapymedicine.medical_treatment030106 microbiologyBiologymedicine.disease_causeMicrobiologyMicrobiology03 medical and health sciencesPlasmidAntibiotic resistanceDrug Resistance BacterialEscherichia colimedicineHumansBacteriophagesEscherichia coliEscherichia coli InfectionsGeneticsBacterial conjugationPathogenic bacteriaAnti-Bacterial AgentsLytic cycleConjugation GeneticHorizontal gene transferPlasmidsFuture Microbiology
researchProduct

2019

Aquaculture production has increased tremendously during the last decades, and new techniques have been developed, e.g., recirculating aquaculture systems (RAS). In RAS, the majority of water volume is circulated via mechanical and biological filters and reused in the tanks. However, the prevention and treatment of diseases in these systems are challenging, as the pathogens spread throughout the system, and the addition of chemicals and antibiotics disrupts the microbiome of the biofilters. The increasing antibiotic resistance has made phage therapy a relevant alternative for antibiotics in food production. Indeed, as host-specific and self-replicating agent they might be optimal for target…

0301 basic medicineMicrobiology (medical)Phage therapymedicine.medical_treatmentFish farming030106 microbiologyBiochemistryMicrobiologyMicrobiologyBacteriophage03 medical and health sciencesAquaculturemedicinePharmacology (medical)14. Life underwaterGeneral Pharmacology Toxicology and Pharmaceuticsbiologybusiness.industryBiofilmbiology.organism_classification6. Clean water030104 developmental biologyInfectious DiseasesFlavobacterium columnareBiofilterRainbow troutbusinessAntibiotics
researchProduct

Identification of a Peptide Produced by Bifidobacterium longum CECT 7210 with Antirotaviral Activity

2016

Rotavirus is one of the main causes of acute diarrhea and enteritis in infants. Currently, studies are underway to assess the use of probiotics to improve rotavirus vaccine protection. A previous work demonstrated that the probiotic strain Bifidobacterium longum subsp. infantis CECT 7210 is able to hinder rotavirus replication both in vitro and in vivo. The present study takes a systematic approach in order to identify the molecule directly involved in rotavirus inhibition. Supernatant protease digestions revealed both the proteinaceous nature of the active substance and the fact that the molecule responsible for inhibiting rotavirus replication is released to the supernatant. Following pur…

0301 basic medicineMicrobiology (medical)RotavirusBifidobacterium longummedicine.medical_treatment030106 microbiologylcsh:QR1-502PeptideBiologymedicine.disease_causeMicrobiologylcsh:Microbiologylaw.inventionMicrobiology03 medical and health sciencesProbioticfluids and secretionslawRotavirusmedicineB. longum subsp. infantis CECT 7210Original Researchchemistry.chemical_classificationProteaseMolecular massProbiotics11-mer peptidebiology.organism_classificationRotavirus vaccineIn vitroProteaseBiochemistrychemistryFrontiers in Microbiology
researchProduct

'Secondary prevention' against female HPV infection: literature review of the role of carrageenan.

2020

Introduction: Human papillomaviruses (HPVs) are common sexually transmitted pathogens, causally associated with cervical cancer and other anogenital cancers, as well as approximately 20% of head and neck cancers. The HPV vaccine is an exceptional primary prevention tool, but the question of adequate secondary-prevention strategies remains open. The aim of this review is to better clarify the role of carrageenan in HPV prevention-strategies. Areas covered: A comprehensive literature search was performed (PubMed/MEDLINE, Embase, Google Scholar, Cochrane Databases) to identify articles on the use of carrageenan against HPV infection. The studies were identified using combinations of the search…

0301 basic medicineMicrobiology (medical)Settore MED/07 - Microbiologia E Microbiologia Clinicamedicine.medical_treatment030106 microbiologyCarrageenan papillomavirus prevention HPV microbicideMEDLINEAlphapapillomavirusBioinformaticsCarrageenanMicrobiology03 medical and health scienceschemistry.chemical_compound0302 clinical medicineImmune systemVirologyMicrobicidemedicineSecondary PreventionAnimalsHumans030212 general & internal medicinePapillomavirus VaccinesCervical cancerbusiness.industryMechanism (biology)Papillomavirus InfectionsHPV infectionmedicine.diseaseSettore MED/40 - Ginecologia E OstetriciaCarrageenanInfectious DiseaseschemistryFemalebusinessAdjuvantExpert review of anti-infective therapy
researchProduct